← Back to headlines
Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition
Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.
17 Feb, 18:07 — 17 Feb, 18:07
Read at source (1 outlet)
Related Stories
Getting the Last Dime Out of Every Mile: A Lesson in Efficiency
4m ago
Mizuho Securities Faces Loss of Lead Underwriter Roles Amid Employee Misconduct Investigation
4m ago
Wal-Mart de Mexico Reports Q4 GAAP EPS of MXN$0.844 and Revenue of MXN$280.98B
4m ago
Centrica Pauses Buybacks Following 40% Earnings Slump
4m ago